Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence
Stopped early · Phase 1
Conditions studied: Glioblastoma Multiforme
In brief
This is a phase 1b study for safety and tolerability of bevacizumab(Avastin)administered into the tumor resection cavity in subjects with Glioblastoma Multiforme (GBM) at first recurrence.
Key facts
- Study ID
- NCT01526837
- Run by
- Brain & Spine Surgeons of New York
- People needed
- 1
- Starts
- 2011-10-01
- Expected to finish
- 2012-01-01
- Last updated by the study team
- 2017-07-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Recurrent Glioblastoma
- At least 12 weeks expected survival (KPS >60)
- 18 years of age or older
- Able and willing to participate
You may not qualify if…
- Any prior diagnosis of any other cancer or other concurrent malignancy.
- Planned use or current use of other investigation therapy.
- Systemic autoimmune disease
- HIV positive
- Concurrent life threatening disease
- Impaired organ function
- Active infection
- Inadequately controlled hypertension
- Congestive heart failure
- Myocardial infection/unstable angina within 6 months
- Stroke within 6 months
- Pheripheral vascular disease
- History of abdominal fistula/gastrointestinal performation
- Non-healing wound
- Coagulation disease
- Known allergy to study treatments
- Pregnant or lactating
Where it is running
- Brain & Spine Surgeons of New York — White Plains, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.